<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02221453</url>
  </required_header>
  <id_info>
    <org_study_id>PersDMEcytokineTA</org_study_id>
    <nct_id>NCT02221453</nct_id>
  </id_info>
  <brief_title>Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide</brief_title>
  <official_title>Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide: an Interventional Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic macular edema refers to swelling (fluid accumulation) in the center of the retina.&#xD;
      The retina is like the film of a camera and is located in the back of the eye. This condition&#xD;
      can develop in diabetics where swelling results from leaking of fluid from the blood vessels&#xD;
      of the eye, into the center of the retina, the macula. If left untreated, this can affect&#xD;
      central vision. The current standard treatment for diabetic macular edema includes&#xD;
      medications injected directly into the eye (intravitreal injections) and laser eye treatment.&#xD;
      The drugs that are injected directly into the eye are known as anti-Vascular Endothelial&#xD;
      Growth Factor (anti-VEGF) agents which help to reduce the leaking. This includes bevacizumab&#xD;
      (Avastin®) and ranibizumab (Lucentis®).&#xD;
&#xD;
      However, some patients do not respond well to these anti-VEGF treatments will be given the&#xD;
      option of switching to an another class of medications, called steroids. Triamcinolone&#xD;
      acetonide is one of these steroids and is also injected directly into the eye. These steroids&#xD;
      will help reduce inflammation and possibly as a consequence, reduce swelling in the eye.&#xD;
&#xD;
      The purpose of this study is to determine what cellular factors affect a patient's treatment&#xD;
      response (amount of swelling reduction) following triamcinolone acetonide intravitreal&#xD;
      injections for diabetic macular edema.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cytokine levels (picograms per mL) between baseline triamcinolone acetonide injection and 3 months</measure>
    <time_frame>3 months after baseline triamcinolone acetonide injection</time_frame>
    <description>The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cytokine levels (picograms per mL) 3 months after 2nd triamcinolone acetonide injection</measure>
    <time_frame>3 months after 2nd triamcinolone acetonide injection</time_frame>
    <description>Note that the 2nd triamcinolone acetonide injection occurs 3 months after baseline injection. The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ocular cytokine levels (picograms per mL) in relation to change in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) in response to steroid treatment</measure>
    <time_frame>3 months after baseline injection</time_frame>
    <description>The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1. Change in ETDRS BCVA is in ETDRS letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular cytokine levels (picograms per mL) in relation to change in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) in response to steroid treatment</measure>
    <time_frame>3 months after 2nd triamcinolone acetonide injection</time_frame>
    <description>The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1. Change in ETDRS BCVA is in ETDRS letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular cytokine levels (picograms per mL) in relation to change in central macular thickness (CMT) measured in micrometers (um) from optical coherence tomography</measure>
    <time_frame>3 months after baseline injection</time_frame>
    <description>The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1. Change in CMT is in micrometers (um).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular cytokine levels (picograms per mL) in relation to change in central macular thickness (CMT) measured in micrometers (um) from optical coherence tomography</measure>
    <time_frame>3 months after 2nd triamcinolone acetonide injection</time_frame>
    <description>The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1. Change in CMT is in micrometers (um).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Triamcinolone Acetonide Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Triamcinolone Acetonide Injectable Suspension 40 mg/mL intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <arm_group_label>Triamcinolone Acetonide Treatment</arm_group_label>
    <other_name>Triesence</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of Non Proliferative Diabetic Retinopathy (NDPR) or Proliferative Diabetic&#xD;
             Retinopathy as confirmed by IntraVenous Fluorescein Angiography (IVFA)&#xD;
&#xD;
          -  Prior treatment with ≥ 6 intravitreal anti-VEGF injections but no treatment in last 4&#xD;
             weeks&#xD;
&#xD;
          -  Less than 10% improvement in Central Macular Thickness on OCT scan and less than 1&#xD;
             line improvement in vision from baseline&#xD;
&#xD;
          -  Less than 10% reduction in macular volume&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Subjects with Type I or II diabetes mellitus&#xD;
&#xD;
          -  snellen Acuity 20/40 to 20/400 and its ETDRS equivalent&#xD;
&#xD;
          -  Ability to provide signed informed consent&#xD;
&#xD;
          -  Capable of complying with study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous intraocular injection of steroid medication.&#xD;
&#xD;
          -  Concurrent ocular disease (wet Age-Related Macular Degeneration, significant&#xD;
             Epiretinal Membrane, vitreomacular traction etc) that would limit visual acuity in the&#xD;
             opinion of the treating physician&#xD;
&#xD;
          -  Proliferative diabetic retinopathy in the study eye or PanRetinal Photocoagulation&#xD;
             within the last 12 months&#xD;
&#xD;
          -  Poor glycemic control HbA1c &gt;9%&#xD;
&#xD;
          -  Prior vitrectomy surgery.&#xD;
&#xD;
          -  Prior intraocular surgery within 3 months in study eye&#xD;
&#xD;
          -  Laser treatment within 3 months of study eye&#xD;
&#xD;
          -  Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or&#xD;
             extensive dermal) within 1 month prior to study enrollment.&#xD;
&#xD;
          -  Known history of Intraocular Pressure (IOP) elevation in response to steroid treatment&#xD;
             in either eye that resulted in any of the following: a) = 10 mm Hg increase in IOP in&#xD;
             response to steroid injection, or b) IOP = 25 mm Hg and required 2 or more&#xD;
             anti-glaucoma medications to keep IOP below 21 mm Hg.&#xD;
&#xD;
          -  Known allergies to study drug or fluorescein&#xD;
&#xD;
          -  History of stroke or acute Myocardial Infarction within 6 months of enrolment&#xD;
&#xD;
          -  Patients receiving dialysis for renal failure&#xD;
&#xD;
          -  Patients currently on systemic immunosuppression&#xD;
&#xD;
          -  Patients with glaucoma&#xD;
&#xD;
          -  Patients who are pregnant.&#xD;
&#xD;
          -  Unwilling or unable to follow or comply with all study related procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajeev Muni, MD MSc FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital Eye Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2014</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Ocular Cytokines</keyword>
  <keyword>Triamcinolone Acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

